A phase II study of neoadjuvant chemotherapy with docetaxel and bevacizumab in patients (pts) with high-risk localized prostate cancer: A Prostate Cancer Clinical Trials Consortium trial
Oh W, Febbo P, Richie J, Fennessy F, Scibelli G, Hayes J, Choueiri T, Tempany C, Taplin M, Ross R. A phase II study of neoadjuvant chemotherapy with docetaxel and bevacizumab in patients (pts) with high-risk localized prostate cancer: A Prostate Cancer Clinical Trials Consortium trial. Journal Of Clinical Oncology 2009, 27: 5060-5060. DOI: 10.1200/jco.2009.27.15_suppl.5060.Peer-Reviewed Original ResearchHigh-risk localized prostate cancerLocalized prostate cancerProstate cancerPSA declineGleason 7Neoadjuvant docetaxelRadical prostatectomyPhase II study of neoadjuvant chemotherapyClinical evidence of activityGrade 3 allergic reactionStudy of neoadjuvant chemotherapyPhase II multicenter trialBladder neck injuryMaximal tumor volumeMedian Gleason scoreTreated with docetaxelPhase II studyIntraoperative rectal injuryCT2 diseaseCT3 diseaseMedian PSARising PSAFebrile neutropeniaGleason 8Gleason score
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply